

MYELOID TRIALS OPEN TO RECRUTIMENT

Disease	Front line or relapsed/refractory	Key entry criteria	Trial name & treatment
CML&AML&MPN	Front line	New or relapsed patients with AML/MDS-EB2 receiving intensive or non-intensive treatment. Patients on supportive care or receiving an allo SCT are ineligible.	PACE= Observational study looking at impact of COVID
		Older (>60) patients with AML or high risk MDS	AML 18= Karyotype not known adverse. 1st cycle DA + Mylotarg vs CPX-351. Other cycles as per trial design dependent on response to cycle 1. AC220 for FLT 3 positive patients
		Patients receiving blinatumomab	Blinatumomab= Observational study
		Adults (19-65) with newly diagnosed with ALL	UKALL 14= Registration only
		De Novo AML, CD33 positive not known adverse karyotype or secondary AML.	AML 19= 1st cycle DA + 2 x Mylotarg vs DA +1 x Mylotarg. Other cycles dependent on response to cycle 1. Midostaurin pilot for FLT-3 positive patients
CML&AML&MPN	Relapsed/ Refractory	Myelofibrosis patients naïve or previously failed ruxalitinib	MANIFEST= Phase 1.
	Observational	A case-control study of patients with Myeloproliferative neoplasms and non-blood relative/friend controls.	MOSAICC= Observational study.